Display options
Cite
Inglin L, Lavikainen P, Jalkanen K, et al. LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model. Sci Rep. 2021;11(1):22603doi: 10.1038/s41598-021-02077-6.
Inglin, L., Lavikainen, P., Jalkanen, K., & Laatikainen, T. (2021). LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model. Scientific reports, 11(1), 22603. https://doi.org/10.1038/s41598-021-02077-6
Inglin, Laura, et al. "LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model." Scientific reports vol. 11,1 (2021): 22603. doi: https://doi.org/10.1038/s41598-021-02077-6
Inglin L, Lavikainen P, Jalkanen K, Laatikainen T. LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model. Sci Rep. 2021 Nov 19;11(1):22603. doi: 10.1038/s41598-021-02077-6. PMID: 34799657; PMCID: PMC8604948.
Copy Download .nbib Format: NLM
Share it on

Sci Rep. 2021 Nov 19;11(1):22603. doi: 10.1038/s41598-021-02077-6.

LDL-cholesterol trajectories and statin treatment in Finnish type 2 diabetes patients: a growth mixture model.

Scientific reports

Laura Inglin, Piia Lavikainen, Kari Jalkanen, Tiina Laatikainen

Affiliations

  1. Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Yliopistonranta 1, 70210, Kuopio, Finland. [email protected].
  2. School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  3. Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Yliopistonranta 1, 70210, Kuopio, Finland.
  4. Finnish Institute for Health and Welfare, Helsinki, Finland.
  5. Joint Municipal Authority for North Karelia Health and Social Services (Siun Sote), Joensuu, Finland.

PMID: 34799657 PMCID: PMC8604948 DOI: 10.1038/s41598-021-02077-6

Abstract

We aimed to identify distinct longitudinal trends of LDL-cholesterol (LDL-C) levels and investigate these trajectories' association with statin treatment. This retrospective cohort study used electronic health records from 8592 type 2 diabetes patients in North Karelia, Finland, comprising all primary and specialised care visits 2011‒2017. We compared LDL-C trajectory groups assessing LDL-C treatment target achievement and changes in statin treatment intensity. Using a growth mixture model, we identified four LDL-C trajectory groups. The majority (85.9%) had "moderate-stable" LDL-C levels around 2.3 mmol/L. The second-largest group (7.7%) consisted of predominantly untreated patients with alarmingly "high-stable" LDL-C levels around 3.9 mmol/L. The "decreasing" group (3.8%) was characterised by large improvements in initially very high LDL-C levels, along with the highest statin treatment intensification rates, while among patients with "increasing" LDL-C (2.5%), statin treatment declined drastically. In all the trajectory groups, women had significantly higher average LDL-C levels and received less frequent any statin treatment and high-intensity treatment than men. Overall, 41.9% of patients had no statin prescribed at the end of follow-up. Efforts to control LDL-C should be increased-especially in patients with continuously elevated levels-by initiating and intensifying statin treatment earlier and re-initiating the treatment after discontinuation if possible.

© 2021. The Author(s).

References

  1. Cardiovasc Diabetol. 2020 Nov 10;19(1):190 - PubMed
  2. BMJ Open. 2013 Nov 04;3(11):e003414 - PubMed
  3. Can J Diabetes. 2020 Mar;44(2):133-138 - PubMed
  4. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38-e81 - PubMed
  5. Br J Clin Pharmacol. 2008 Sep;66(3):405-10 - PubMed
  6. BMJ Open. 2016 Jun 03;6(6):e011306 - PubMed
  7. Cardiovasc Drugs Ther. 2017 Jun;31(3):303-309 - PubMed
  8. Eur Heart J. 2017 Aug 21;38(32):2459-2472 - PubMed
  9. Eur Heart J. 2020 Jan 1;41(1):111-188 - PubMed
  10. N Engl J Med. 2018 Aug 16;379(7):633-644 - PubMed
  11. Curr Atheroscler Rep. 2020 Jun 18;22(8):37 - PubMed
  12. Medicine (Baltimore). 2015 Dec;94(50):e2193 - PubMed
  13. Int J Qual Health Care. 2006 Sep;18 Suppl 1:26-30 - PubMed
  14. J Am Heart Assoc. 2019 Apr 2;8(7):e011765 - PubMed
  15. J Manag Care Spec Pharm. 2019 Oct;25(10):1053-1062 - PubMed
  16. J Lipid Res. 2019 Mar;60(3):648-660 - PubMed
  17. J Am Heart Assoc. 2019 Jun 4;8(11):e011433 - PubMed
  18. BMJ. 2016 Jun 28;353:i3283 - PubMed
  19. Pharmacol Res. 2007 Feb;55(2):81-95 - PubMed
  20. BMJ Open. 2017 Aug 21;7(8):e012613 - PubMed
  21. Diabetes Care. 2013 Sep;36(9):2628-38 - PubMed
  22. Diabetes Care. 2013 Oct;36(10):3162-8 - PubMed
  23. Lancet. 2017 Jun 24;389(10088):2473-2481 - PubMed
  24. BMJ Open. 2017 Feb 17;7(2):e013255 - PubMed
  25. Atherosclerosis. 2018 Jan;268:99-107 - PubMed
  26. Annu Rev Clin Psychol. 2010;6:109-38 - PubMed
  27. J Am Coll Cardiol. 2019 Jul 9;74(1):70-79 - PubMed
  28. PLoS One. 2016 Jan 25;11(1):e0146272 - PubMed
  29. J Clin Lipidol. 2014 Jan-Feb;8(1):117-25 - PubMed
  30. Cardiovasc Diabetol. 2018 Jun 8;17(1):83 - PubMed
  31. Scand J Prim Health Care. 2010 Mar;28(1):47-54 - PubMed
  32. Diabetes Res Clin Pract. 2009 Apr;84(1):e9-e11 - PubMed
  33. Am Heart J. 2013 Sep;166(3):597-603 - PubMed
  34. Circulation. 2014 Jun 24;129(25 Suppl 2):S1-45 - PubMed
  35. BMC Fam Pract. 2020 Dec 4;21(1):253 - PubMed
  36. Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):243-7 - PubMed
  37. Eur Heart J. 2016 Mar 14;37(11):908-916 - PubMed
  38. Sci Rep. 2017 Oct 4;7(1):12648 - PubMed
  39. PLoS One. 2019 Jan 17;14(1):e0201196 - PubMed
  40. J Clin Lipidol. 2017 Mar - Apr;11(2):485-494 - PubMed
  41. Diabetes Care. 2019 Jan;42(Suppl 1):S103-S123 - PubMed
  42. Health Serv Res Manag Epidemiol. 2019 May 30;6:2333392819852879 - PubMed
  43. Int J Endocrinol. 2015;2015:570198 - PubMed

Publication Types

Grant support